Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 7, Issue 1, 2009

The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship betw Read More

Cancer cells continuously adapt to their local and external milieu during their growth by acquiring new biochemical and cellular properties. For example, in many cancer cells, glycolytic capacity increases even in non-hypoxic conditions. The latter phenomenon is known as ‘aerobic glycolysis’ and has become a central topic in the field of cancer biology. Aerobic glycolysis is induced by several factors including dysfunction of mit Read More

The ATP-Binding-Cassette (ABC) superfamily of transporters, implicated in the traffic of drugs/xenobiotics across membranes, represents one of the larger families of drug-response genes. Many of these transporters are expressed at apical membranes of barrier tissues where they offer protection against orally ingested or airborne toxins. They can also modulate the absorption of orally administered drugs to influence dr Read More

In recent years the design of association studies published in pharmacogenetics journals has markedly changed and the corresponding analyses have increasingly involved a large number of SNPs, genes and patients, and a transition from the candidate gene strategy to the whole-genome association (WGA) studies. This review provides an overview of the recent advances that have led to this transition, lists the advantages Read More

Colorectal cancer is the second most common malignancy in the U.S. In the past 15 years we witnessed the development of new anticancer agents for patients with colorectal cancer. A multitude of therapeutic options creates a challenge for a physician to select the most efficacious and least toxic agent for an individual patient. To this end, pharmacogenomic variability in metabolic pathways for fluorouracil, capecitabine, irinot Read More